Patents by Inventor Michael Torgov

Michael Torgov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DLL3 MODULATORS AND METHODS OF USE
    Publication number: 20170000901
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 15, 2016
    Publication date: January 5, 2017
    Applicant: AbbVie Stemcentrx LLC
    Inventors: Robert A. STULL, Laura SAUNDERS, Scott J. DYLLA, Orit FOORD, David LIU, Michael TORGOV, Hui SHAO
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9486537
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 8, 2016
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9481727
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 1, 2016
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9480757
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 1, 2016
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Antibodies Directed To GPNMB And Uses Thereof
    Publication number: 20160311919
    Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
    Type: Application
    Filed: February 25, 2016
    Publication date: October 27, 2016
    Inventors: Feng Xiao, Xiao-Chi Jia, Meina Liang, Orit Foord, Scott Klakamp, Kam Fai Tse, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael E. Jeffers, William J. LaRochelle, Gulshan Ara, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20160263243
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 14, 2016
    Publication date: September 15, 2016
    Inventors: Daulet SATPAYEV, Robert Kendall MORRISON, Karen Jane Meyrick MORRISON, Jean GUDAS, Aya JAKOBOVITS, Michael TORGOV, Zili AN
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS
    Publication number: 20160256563
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 15, 2016
    Publication date: September 8, 2016
    Inventors: Michael TORGOV, Robert Kendall MORRISON, Aya JAKOBOVITS, Jean GUDAS, Zili AN
  • Anti-DLL3 antibody drug conjugates
    Publication number: 20160251431
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: April 21, 2016
    Publication date: September 1, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. STULL, Laura SAUNDERS, Scott J. DYLLA, Orit FOORD, David LIU, Michael TORGOV, Hui SHAO
  • Anti-DLL3 antibody drug conjugates
    Publication number: 20160250348
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: April 21, 2016
    Publication date: September 1, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. STULL, Laura SAUNDERS, Scott J. DYLLA, Orit FOORD, David LIU, Michael TORGOV, Hui SHAO
  • Anti-DLL3 antibody drug conjugates
    Publication number: 20160228571
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 11, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. STULL, Laura SAUNDERS, Scott J. DYLLA, Orit FOORD, David LIU, Michael TORGOV, Hui SHAO
  • KITS CONTAINING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20160158379
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: January 25, 2016
    Publication date: June 9, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Methods of making DLL3 antibody drug conjugates
    Patent number: 9358304
    Abstract: Novel modulatators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: June 7, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • METHODS OF DELIVERING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20160151513
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: January 25, 2016
    Publication date: June 2, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-DLL3 antibodies
    Patent number: 9353182
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: May 31, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Kits containing DLL3 antibody drug conjugates
    Patent number: 9352051
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: May 31, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Methods of delivering DLL3 antibody drug conjugates
    Patent number: 9345784
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: May 24, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • METHODS OF MAKING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20160136296
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. STULL, Laura SAUNDERS, Scott J. DYLLA, Orit FOORD, David LIU, Michael TORGOV, Hui SHAO
  • MULTIVALENT DLL3 ANTIBODIES
    Publication number: 20160130331
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: January 11, 2016
    Publication date: May 12, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Multivalent DLL3 antibodies
    Patent number: 9334318
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: May 10, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Nucleic acid molecules encoding antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 9314538
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 19, 2016
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An